Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease

Gene editing with the CRISPR-Cas9 system could revolutionize hematopoietic stem cell (HSC)-targeted gene therapy for hereditary diseases, including sickle cell disease (SCD). Conventional delivery of editing tools by electroporation limits HSC fitness due to its toxicity; therefore, efficient and no...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Ther Methods Clin Dev
Auteurs principaux: Uchida, Naoya, Drysdale, Claire M., Nassehi, Tina, Gamer, Jackson, Yapundich, Morgan, DiNicola, Julia, Shibata, Yoshitaka, Hinds, Malikiya, Gudmundsdottir, Bjorg, Haro-Mora, Juan J., Demirci, Selami, Tisdale, John F.
Format: Artigo
Langue:Inglês
Publié: American Society of Gene & Cell Therapy 2021
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8005818/
https://ncbi.nlm.nih.gov/pubmed/33816645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtm.2021.02.022
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires